Stocks & Investing
Tue, April 14, 2020
[ 12:00 AM ] - WOPRAI
Mon, March 30, 2020
[ 12:00 AM ] - WOPRAI
Tue, February 11, 2020
[ 12:00 AM ] - WOPRAI
Fri, February 7, 2020
[ 12:00 AM ] - WOPRAI
Fri, January 10, 2020
[ 12:00 AM ] - WOPRAI
Fri, March 22, 2019
[ 12:00 AM ] - WOPRAI
Thu, February 28, 2019
[ 12:00 AM ] - WOPRAI
Mon, December 17, 2018
[ 12:00 AM ] - WOPRAI
Mon, August 13, 2018
[ 12:00 AM ] - WOPRAI
Thu, June 21, 2018
[ 12:00 AM ] - WOPRAI
Fri, September 15, 2017
[ 12:00 AM ] - WOPRAI
Fri, August 11, 2017
[ 12:00 AM ] - WOPRAI
Thu, March 2, 2017
Mon, April 27, 2015
[ 12:00 AM ] - WOPRAI
Mon, January 5, 2015
[ 12:00 AM ] - WOPRAI
Thu, July 24, 2014
[ 12:00 AM ] - WOPRAI
Thu, April 24, 2014
[ 12:00 AM ] - WOPRAI
Wed, January 8, 2014 Christopher Marai Maintained (ALNY) at Sell and Held Target at $74 on, Apr 14th, 2020
Christopher Marai of Nomura, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Sell and Held Target at $74 on, Apr 14th, 2020.
Christopher has made no other calls on ALNY in the last 4 months.
There are 3 other peers that have a rating on ALNY. Out of the 3 peers that are also analyzing ALNY, 0 agree with Christopher's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Christopher
- David Lebovitz of "Morgan Stanley" Maintained at Buy with Decreased Target to $148 on, Friday, February 7th, 2020
- Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $190 on, Thursday, December 19th, 2019
- Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy with Increased Target to $176 on, Wednesday, December 18th, 2019
